Active — Not RecruitingEarly Phase 1

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

United States18 participantsStarted 2024-08-12

Plain-language summary

The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hair growth cycle.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * women eighteen years of age or older * biopsy-proven and /or clinical diagnosis of CCCA Stage II-IV * on stable treatment without changes for at least three months * recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology Exclusion Criteria: * males

What they're measuring

Amount of hair loss regression

Timeframe: Baseline

Amount of hair loss regression

Timeframe: Month 2

Amount of hair loss regression

Timeframe: Month 4

Amount of hair loss regression

Timeframe: Month 6

Trial details

NCT IDNCT05416333

SponsorWake Forest University Health Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Central Centrifugal Cicatricial Alopecia trials